FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

5 CGMP Issues Cited in Ross Healthcare Inspection

FDA warns Ross Healthcare, in Lynden, WA, about CGMP violations in its production of finished drugs.

latest-news-card-1
Medical Devices

Fresenius Recalls Ivenix Pumps Over Software Issue

Fresenius Kabi recalls its Ivenix Large Volume Pump due to a software issue.

latest-news-card-1
Human Drugs

FDA Division of Applied Regulatory Science Releases Annual Report

CDER Division of Applied Regulatory Science (DARS) has published its 2025 Annual Report, highlighting significant research advances, collaborative sci...

latest-news-card-1
Human Drugs

Rep. Gottheimer Introduces 5 Bipartisan Rare Disease Bills

Rep. Josh Gottheimer introduces several bills to mark Rare Disease Week.

latest-news-card-1
Human Drugs

CDER Plans 81 New, Revised Guidances in 2026

FDA releases a list of 81 new and revised guidances in 12 categories that CDER plans to issue this calendar year.

latest-news-card-1
Human Drugs

Lillys Oral GLP-1 Orforglipron Beats Oral Semaglutide in Trial

Eli Lilly reports favorable efficacy data on its investigational oral GLP-1 receptor agonist orforglipron, showing significantly greater reductions in...

latest-news-card-1
Human Drugs

FDA OKs Dupixent For Allergic Fungal Rhinosinusitis

FDA approves a Sanofi and Regeneron Pharmaceuticals BLA supplement for Dupixent (dupilumab) and its use for treating adults and children ages 6 and ol...

latest-news-card-1
Medical Devices

Alert on Abiomed Heart Pumps

FDA issues an early alert about a potentially high-risk problem involving certain heart pump components manufactured by Abiomed, warning that a malfun...

latest-news-card-1
Biologics

FDA Accepts Vanda BLA for Rare Skin Disorder Drug

FDA accepts for review a Vanda Pharmaceuticals BLA for imsidolimab, a potential new treatment for generalized pustular psoriasis.

latest-news-card-1
Human Drugs

Novo Nordisk Triple G Weight Loss Drug Shows Promise

Novo Nordisk reports favorable weight-loss data with its triple agonist UBT251 in a Phase 2 trial in China.